Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis.

2014-11
Journal of clinical gastroenterology 48(Supplement 1)
- Antonio A Niccoli
- Anna L Artesi
- Francesco Candio
- Sara Ceccarelli
- Rita Cozzali
- Luigi Ferraro
- Donatella Fiumana
- Manuela Mencacci
- Maurizio Morlupo
- Paola Pazzelli
- Laura Rossi
- Marco Toscano
- Lorenzo Drago

PubMed: 25291124
DOI: 10.1097/mcg.0000000000000233

Study Design

Type: Clinical Trial
Sample size: n = 43
Population: 43 patients aged from 0 to 11 years with atopic dermatitis
Methods: treated with the probiotic strain L. salivarius LS01
Blinding: Open-label
Duration: 4 weeks
Funding: Unclear

Goals

The goal of this study was to evaluate the clinical efficacy of an intake of Lactobacillus salivarius LS01 (DSM 22775) for the treatment of atopic dermatitis (AD) in children.

Background

AD is an inflammatory and pruritic chronic relapsing skin disorder with multifactorial etiopathology. Some evidence suggests that probiotics may improve AD by modulating the immune system and the composition of intestinal microbiota.

Study

A total of 43 patients aged from 0 to 11 years were enrolled in the study (M/F ratio=1:1) and treated with the probiotic strain L. salivarius LS01. Clinical efficacy of probiotic treatment was assessed from baseline by changes in itch index and in the objective SCORAD/SCORAD index.

Results

Patients being given probiotic treatment showed a significant improvement in clinical parameters (SCORAD and itch values) from baseline. The reduction in SCORAD and itch index observed after 4 weeks of treatment also persisted after the cessation of probiotic supplementation.

Conclusions

L. salivarius LS01 seems to be able to improve the quality of life of children affected by AD and, as a consequence, it may have promising clinical and research implications.